A 42-year-old woman with cystic fibrosis presents with acute exacerbation of chronic Pseudomonas aeruginosa lung infection. She is started on IV tobramycin 5 mg/kg once daily. Baseline serum creatinine is 0.9 mg/dL, and audiometry shows normal hearing. On day 8 of therapy, she reports bilateral high-frequency hearing loss and tinnitus. Audiometry confirms sensorineural hearing loss at 4–8 kHz. Serum creatinine remains 0.9 mg/dL. What is the most appropriate action?

Explanation

## Clinical Diagnosis: Aminoglycoside-Induced Ototoxicity This patient has developed **irreversible sensorineural hearing loss** secondary to tobramycin, a known ototoxic aminoglycoside. **Key Point:** Aminoglycoside-induced ototoxicity is **IRREVERSIBLE** and progresses even after drug discontinuation if not caught early. High-frequency loss (4–8 kHz) is the classic pattern. ## Mechanism of Aminoglycoside Ototoxicity 1. **Vestibulotoxicity & Cochleotoxicity** — aminoglycosides accumulate in inner ear fluid (perilymph, endolymph) 2. Damage to sensory hair cells in cochlea (auditory) and vestibule (balance) 3. Irreversible destruction of hair cells → permanent hearing loss 4. **Dose- and duration-dependent** — cumulative toxicity 5. High-frequency loss precedes lower-frequency loss **High-Yield:** Unlike nephrotoxicity (which may partially recover), ototoxicity is **PERMANENT**. Early detection via audiometry is critical. ## Risk Factors for Aminoglycoside Ototoxicity | Risk Factor | Mechanism | |---|---| | **Prolonged therapy (>10 days)** | Cumulative inner ear accumulation | | **High cumulative dose** | Dose-dependent toxicity | | **Renal impairment** | ↓ Clearance → accumulation | | **Age >60 years** | Age-related cochlear degeneration | | **Concomitant loop diuretics** | Synergistic ototoxic effect | | **Dehydration** | ↑ Drug concentration | | **Baseline hearing loss** | Pre-existing vulnerability | | **Genetic predisposition** | Mitochondrial mutations (rare) | **Clinical Pearl:** Tobramycin is **MORE ototoxic** than gentamicin or amikacin. In cystic fibrosis patients receiving prolonged IV tobramycin, ototoxicity is a recognized complication. ## Management Algorithm for Aminoglycoside Ototoxicity ```mermaid flowchart TD A[Patient on aminoglycoside develops hearing loss]:::outcome B{Confirmed sensorineural hearing loss on audiometry?}:::decision A --> B B -->|Yes| C[DISCONTINUE aminoglycoside immediately]:::urgent B -->|No| D[Continue with baseline audiometry] C --> E[Switch to alternative agent]:::action E --> F[Audiologic follow-up at 4-6 weeks]:::action F --> G[Hearing loss is PERMANENT]:::outcome D --> H[Repeat audiometry in 3-5 days] ``` **Mnemonic: STOP OTOTOXIC DRUGS — S.O.D.** - **S**ensorineural loss detected → **STOP** immediately - **O**totoxicity is **IRREVERSIBLE** - **D**iscontinue and switch agents ## Why Discontinuation Is Mandatory 1. **Irreversibility** — continued dosing will cause further, permanent hearing loss 2. **Progression** — ototoxicity may worsen even after drug discontinuation (delayed effect) 3. **Quality of life** — hearing loss severely impacts communication and function 4. **Alternative agents available** — fluoroquinolones (ciprofloxacin, levofloxacin) are effective for P. aeruginosa in CF **Warning:** Do NOT reduce dose and continue — this delays intervention and allows progressive irreversible damage. Ototoxicity is NOT dose-reversible like nephrotoxicity. ## Why Inhaled Tobramycin Is Not the Answer Here Inhaled tobramycin (300 mg twice daily) is used for chronic P. aeruginosa suppression in CF, but: - Patient already has **systemic ototoxicity** from IV tobramycin - Switching to inhaled form does NOT reverse existing hearing loss - Inhaled route still has systemic absorption (10–20% bioavailability) - Patient needs a **completely different drug class** (fluoroquinolone or cephalosporin) [cite:KD Tripathi 8e Ch 49; Harrison 21e Ch 173]